Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized comparison of vonoprazan-based and bismuth quadruple regimens for Helicobacter pylori eradication
ChiCTR2200056375Phase 4Recruiting
- Sponsor
- The University of Hong Kong-Shenzhen Hospital
- Start
- Feb 2022
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vonoprazan, amoxicillin, clarithromycin, esomeprazole, tetracycline and 2 more in Helicobacter pylori infection (3 arms), sponsored by The University of Hong Kong-Shenzhen Hospital. Primary endpoint: Helicobacter pylori eradication by 13C urea breath test. Started Feb 2022; status: recruiting.
02
Drugs
vonoprazanamoxicillinclarithromycinesomeprazoletetracycline
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on ChiCTR2200056375.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056375.